Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Newly Diagnosed Glioblastoma
NCT03899857Phase 2Active, not recruiting
- Sponsor
- University of Zurich
- Start
- Oct 2020
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in glioblastoma (GBM), sponsored by University of Zurich. Primary endpoint: Overall Survival at 12 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03899857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899857.